The surgical suture MONOFAST is indicated for holding tissue in contact or for supplementing soft tissues, excluding cardiovascular tissues and central nervous system tissues. Its use is not indicated in ophthalmological and microsurgical procedures.

The implantation of the synthetic absorbable surgical suture MONOFAST initially causes a minimal local inflammation of the tissues, characteristic of the reaction to a foreign body, followed by the development of fibrous connective tissue.

A gradual loss of strength and mass of the suture occurs due to absorption through the process of hydrolysis. During the absorption of the MONOFAST suture, an initial loss of strength is noted without significant loss of its mass.

• Residual strength of 68-78% after one week.
• By the end of the second week, the residual strength reaches up to 30%.
• The complete absorption of the suture occurs over a period of 90 to 110 days.
• The total initial strength is lost within 28 days.